AMRN Share Price Performance
US$16.43
5.93 (56.51%)
49.4% overvalued intrinsic discount
US$11.00
Fair Value
Price US$16.43
AnalystConsensusTarget US$11.00
Fair ValueUS$11.00
Share Pricen/a
Amarin Corporation plc Stock Price
- 1 Narratives written by author
- 1 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
AMRN Community Narratives
AN
Fair Value US$11 49.4% overvalued intrinsic discount
International Growth With Recordati Will Face Risks And Rewards
0users have liked this narrative
1users have commented on this narrative
11users have followed this narrative
International Growth With Recordati Will Face Risks And Rewards
Key Takeaways Heavy reliance on international expansion and partner execution may not sufficiently offset domestic declines due to regulatory, pricing, and market access risks. Single-product concentration and shift to royalty revenue heighten earnings unpredictability and exposure to generics and competitive pressures.Read more
0users have liked this narrative
1users have commented on this narrative
11users have followed this narrative
AN
US$11
49.4% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-13.28% p.a.
Profit Margin
3.06%
Future PE
64.96x
Share price in 2028
US$13.51
Recently Updated Narratives
AN
International Growth With Recordati Will Face Risks And Rewards
Fair Value: US$11 49.4% overvalued intrinsic discount
11 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Amarin Corporation plc Key Details
About AMRN
- Founded
- 1989
- Employees
- 275
- CEO
- WebsiteView website
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.
